A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2004
11/18/2004	WO2004024755A3 Sarcolysyl derivatives and method for the production thereof
11/18/2004	WO2004011902A3 Improved systems and methods for analysis of protein post-translational modification
11/18/2004	WO2004007673A3 Neuronal gene expression patterns
11/18/2004	WO2003102149A3 Identification of a novel bhd gene
11/18/2004	WO2003079979A3 Method for treating congestive heart failure
11/18/2004	WO2003038043A3 Combinations of dr5 antibody and other therapeutic agents
11/18/2004	WO2002090499A3 ss-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME
11/18/2004	WO2002086087A3 Cytokine protein family
11/18/2004	US20040231009 Using variation in sensory organ developmental genes to diagnose and treat nervous system disorders; tissue engineering and gene therapy
11/18/2004	US20040231005 Comprises proteolytic enzymes for use as tools to identify modulators for treatment and prevention of gastrointestinal, cell proliferative and inflammatory diseases
11/18/2004	US20040230380 Novel proteins with altered immunogenicity
11/18/2004	US20040230051 Comprises nucleotide sequences coding b lymphocyte antigens for use as tool in prevention and treatment of cell proliferative disorders; immunotherapy
11/18/2004	US20040230043 Novel neurotrophic factors
11/18/2004	US20040230039 Nucleotide sequences coding interleukin-1b converting enzyme comprising death domains for identifying modulators of fatty acid synthase and treatment of cachexia, viral infection and cell proliferative disorders
11/18/2004	US20040230037 Chemokine receptor materials and methods
11/18/2004	US20040230035 protease/thrombin inhibitors
11/18/2004	US20040230034 Hybrid heterodimeric protein hormone and method of using same
11/18/2004	US20040230033 Peptides containing electrophilic group having ability to undergo nucleophilic attack with active site cysteine residues in cysteine proteinase enzymes; inhibitors such as staphylococcal surface protein sorting A (SrtA); blot analysis
11/18/2004	US20040230032 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
11/18/2004	US20040229936 sesquiterpene lactones having a gamma -lactone fused with a 10-membered ring, an 8-membered ring that is further fused with a 4-membered ring, a 7-membered ring that is further fused with a 5-membered ring, or a 6-membered ring that is further fused with a 6-membered ring.
11/18/2004	US20040229922 Sulfur compounds such as phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate, used for prevention of viral diseases and replication
11/18/2004	US20040229912 Polymeric delivery formulations of leuprolide with improved efficacy
11/18/2004	US20040229882 dipeptide or tripeptide MC-1R and MC-4R agonists
11/18/2004	US20040229878 Treating a degenerative disc disease in an intervertebral disc having a nucleus pulposus and an annulus fibrosus; inhibitor are interleukin, tumor necrosis factor, prostaglandins; offers aging resistance
11/18/2004	US20040229857 Neurotherapeutic composition and method
11/18/2004	US20040229849 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
11/18/2004	US20040229843 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
11/18/2004	US20040229842 Use of lipid conjugates in the treatment of diseases
11/18/2004	US20040229834 PREFERENTIAL CLASSIFICATON BETWEEN CANCER CELLS; OBTAIN SAMPLE, MONITOR SAMPLE FOR PREFERENTIAL ENZYMATIC ACTIVITY, EVALUATE DIFFERENTIATED CELLS; for of detecting presence or absence or level of a polynucleotide sequence encoding heparanase in a biological sample
11/18/2004	US20040229833 Therapeutic use of cis-element decays in vivo
11/18/2004	US20040229832 Vaccines containing ribavirin and methods of use thereof
11/18/2004	US20040229829 Enzyme inhibitors for metabolic redirection
11/18/2004	US20040229828 Administering a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide at least 10 nucleotides in length
11/18/2004	US20040229823 For use in therapy of growth metabolic disorders
11/18/2004	US20040229822 Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof
11/18/2004	US20040229819 Hemiasterlin derivatives and uses thereof
11/18/2004	US20040229818 Hepatitis C inhibitor compound
11/18/2004	US20040229816 Administering to the animal or human therapeutically effective amounts in unit dosage form comprising a carrier and at least one secretase inhibitor for therapy of tumors or proliferative disorders in an animal or human
11/18/2004	US20040229815 Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
11/18/2004	US20040229814 Methods and compositions for protecting against cataract development associated with vitrectomies
11/18/2004	US20040229813 Pharmaceutical preparations for treatments of diseases and disorders of the breast
11/18/2004	US20040229811 Compounds and methods for modulating desmosomal cadherin-mediated functions
11/18/2004	US20040229810 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; kits
11/18/2004	US20040229808 Cosmetic compositions containing short bioactive peptides
11/18/2004	US20040229807 employing combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin
11/18/2004	US20040229806 Hirulog-like peptide and gene therapy
11/18/2004	US20040229804 Tribonectins
11/18/2004	US20040229803 Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
11/18/2004	US20040229802 Methods and compositions for treating ocular disease
11/18/2004	US20040229801 Provides anti-fungal compounds, including peptides and peptidomimetics having anti-fungal activity alone, and in combination with other agents that have anti-fungal activity, and methods of using the compounds for killing or inhibit growth of yeast, mold, slimes
11/18/2004	US20040229800 Stimulating nerve cell growth in a subject by administering a bastadin compound or its analogs
11/18/2004	US20040229799 Saposin C-DOPS: a novel anti-tumor agent
11/18/2004	US20040229798 Method for stabilizing blood pressure in hemodialysis subjects
11/18/2004	US20040229797 Protein that comprises an amino-acid in which one or several amino acids are deleted, substituted or added, and has effects of controlling cell migration and cell death in L-FILIP, S-FILIP, or other amino-acid sequence
11/18/2004	US20040229796 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
11/18/2004	US20040229795 For oncological diseases and diseases accompanying neovascularization, immune complex-mediated and autoimmune diseases, viral infections, fibrotic and granulomatous diseases, allergic diseases, degenerative diseases of the nervous system and arteriosclerosis
11/18/2004	US20040229794 Lipophilic drug delivery vehicle and methods of use thereof
11/18/2004	US20040229793 Compositions and methods for less immunogenic protein formulations
11/18/2004	US20040229792 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
11/18/2004	US20040229791 Modulating activity of growth factor in sample which contains an activated alpha 2-macroglobulin by contacting sample with fatty acid to inhibit formation of a complex between growth factor and activated alpha 2-macroglobulin, wherein the fatty acid binds to the activated alpha 2-macroglobulin
11/18/2004	US20040229790 Substance having an activity which modulates or inhibits proliferation of AILIM(activation inducible lymphocyte immunomodulatory molecule)-expressing cells or production of a cytokine; for treatment of rheumatoid arthritis, osteoarthritis
11/18/2004	US20040229789 Sepsis; hemorrhages
11/18/2004	US20040229788 Cell surface molecule mediating cell adhesion and signal transmission
11/18/2004	US20040229787 Transforming growth factor alpha Hlll
11/18/2004	US20040229786 Autologous treatment of degenerated disc with cells
11/18/2004	US20040229785 Screening methods to identify treatments for autoimmune disease
11/18/2004	US20040229784 Administering peptide hormones derived from atrial natriuretic factors/peptides (ANP), atriopeptin, as anticarcinogenic agents
11/18/2004	US20040229783 Inhibiting an inflammatory response in a tissue comprising leptin receptor positive cells, by administering to the tissue an agent that inhibits the signaling activity of the leptin receptor that mediates intestinal inflammation, thereby inhibiting the inflammatory response in the tissue
11/18/2004	US20040229780 KappaM-conopeptides as organ protectants
11/18/2004	US20040229779 NOVX nucleic acids and their encoded polypeptides; diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g., detection of a variety of cancers.
11/18/2004	US20040229778 Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
11/18/2004	US20040229777 Crystalline phases of a potent HCV inhibitor
11/18/2004	US20040229776 Pharmaceutical compositions for hepatitis C viral protease inhibitors
11/18/2004	US20040229775 Bactericide drug
11/18/2004	US20040229774 administering a long acting insulin; also treating diabetic dyslipidemia and atherosclerosis in a patient with IFG, IGT or Type 2 diabetes, particularly early Type 2 diabetes
11/18/2004	US20040229773 Methods and compositions for increasing the anaerobic working capacity in tissues
11/18/2004	US20040229772 vaccines which are specific against the class of E. coli that gives rise to antibodies that cross-react with and cross-protect against the more common members of the CS4-CFA/I family
11/18/2004	US20040229358 Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
11/18/2004	US20040229339 Comprises neisseria membrane protein for use as tool in generation of vaccine to prevent infection and sepsis in infants
11/18/2004	US20040229338 Using transgenic and attenuated salmonella comprising tumor modulatory proteins and pharmceutical conjugate to treat cell proliferative disorders; targeted tissue therapy
11/18/2004	US20040229334 Process for manufacture of nematode-extracted anticoagulant protein (NAP)
11/18/2004	US20040229333 Electroprocessed fibrin-based matrices and tissues
11/18/2004	US20040229331 Novel human kinase and polynucleotides encoding the same
11/18/2004	US20040229318 Erythropoietin conjugate compounds with extended half-lives
11/18/2004	US20040229317 Nucleotide sequences coding amino acid transport protein for use in identifying modulator for treatment of cell proliferative and tissue distribution disorders
11/18/2004	US20040229316 Comprises membrane proteins for use in identifying modultaors for treatment, prevention and diagnosis of inflammatory, central nervous system or gastrointestinal disorders; drug screening
11/18/2004	US20040229314 22438, 23553, 25278, and 26212 novel human sulfatases
11/18/2004	US20040229304 Transport proteins; for drug screening/diagnosis/therapy; genetic engineering; bacteriophages
11/18/2004	US20040229298 Methods and compositions for treating cervical cancer
11/18/2004	US20040229292 Enhancing memory and learning via administering neurodegenerative cells and/or animal models fibroblast growth factor-18; gene therapy and tissue targeted therapy
11/18/2004	US20040229291 Screening and therapeutic methods relating to neurogenesis
11/18/2004	US20040229289 Antigen binding peptides (abtides) from peptide libraries
11/18/2004	US20040229286 Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
11/18/2004	US20040229282 Controlling and treating sepsis and thrombosis using immunoglobulin which specifically binds tissue factor and prevents binding by blood coagulation factor; immunotherapy and blood disorders
11/18/2004	US20040229278 Protein from plasma membrane of adipocytes; controlling glucose uptake
11/18/2004	US20040229275 Comprises nucleotide sequences coding membrane transport protein for use in identifying modulators for treatment of low high density lipoprotein concentration, high triglyceride levels and/or cardiovascular disorders
11/18/2004	US20040229267 Tumor suppressor pathway in C. elegans
11/18/2004	US20040229266 RNA interference mediating small RNA molecules
11/18/2004	US20040229265 Amino-modified polysaccharides and methods of generating and using same
11/18/2004	US20040229260 Comprises nucleotide sequences coding interleukin-1b converting enzyme ligand for use in diagnosis, prevention and treatment of autoimmune, connective tissue and crohn's diseases

1 ... 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 ... 3163